688488.SH
艾迪药业
SSE · Healthcare · Biotechnology · CN
CNY 15.93
−3.40%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 699.3M | 719.2M | 417.8M | 411.4M | 244.2M |
| Cost of Revenue | 221.5M | 238.8M | 188.3M | 221.3M | 139.4M |
| Gross Profit | 477.8M | 480.4M | 229.5M | 190.0M | 104.8M |
| Operating Expenses | |||||
| R&D Expense | 85.1M | 87.4M | 89.9M | 63.2M | 63.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 88.0M | 90.0M | 96.9M | 95.3M | 92.1M |
| Selling & Marketing Expense | 252.7M | 246.1M | 155.0M | 104.4M | 75.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 451.4M | 449.0M | 360.4M | 279.3M | 235.2M |
| Cost and Expenses | 672.9M | 687.9M | 548.7M | 500.6M | 374.6M |
| Operating Income (EBIT) | 34.4M | 48.1M | (164.5M) | (92.0M) | (142.1M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 8.9M | 24.6M | (166.0M) | (92.1M) | (142.4M) |
| Income Tax Expense | 12.3M | 16.6M | (27.2M) | (16.0M) | (18.3M) |
| Bottom Line | |||||
| Net Income | (27.5M) | (19.5M) | (141.2M) | (76.1M) | (124.1M) |
| Earnings from Cont. Ops | (3.3M) | 8.1M | (138.8M) | (76.1M) | (124.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (27.5M) | (19.5M) | (141.2M) | (76.1M) | (124.1M) |
| Per Share | |||||
| Basic EPS | (CN¥0.07) | (CN¥0.05) | (CN¥0.34) | (CN¥0.18) | (CN¥0.30) |
| Diluted EPS | (CN¥0.07) | (CN¥0.05) | (CN¥0.34) | (CN¥0.18) | (CN¥0.30) |
| Revenue Per Share | CN¥1.84 | CN¥1.84 | CN¥1.01 | CN¥0.97 | CN¥0.59 |
| Shares | |||||
| Basic Shares Outstanding | 380.3M | 390.6M | 415.3M | 422.6M | 413.6M |
| Diluted Shares Outstanding | 380.3M | 390.6M | 415.3M | 422.6M | 413.6M |
| Profitability Metrics | |||||
| EBITDA | — | 106.0M | (113.0M) | (47.5M) | (105.3M) |
| D&A | — | 58.0M | 51.4M | 44.6M | 36.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026